A comparison of 2013 and 2022 data shows that cancer costs are not uniformly rising. Costs decreased for metastatic colorectal cancer but increased for both metastatic non–small cell lung cancer and multiple myeloma.
|Articles|July 12, 2013
Supplements and Featured Publications
- The Clinical, Social, and Economic Implications of Neurogenic Bladder in Managed Care: Optimizing Pa
- Volume 19
- Issue 10 Suppl
Post Test: The Clinical, Social, and Economic Implications of Neurogenic Bladder in Managed Care: Optimizing Patient Management and Outcomes
Advertisement
Instructions
After reading “The Clinical, Social, and Economic Implications of Neurogenic Bladder in Managed Care: Optimizing Patient Management and Outcomes,” complete the program evaluation and select the single best answer to each of the posttest questions.
A statement of continuing education credit will be provided to those physicians and pharmacists who successfully complete and return the answer form and program evaluation and receive a passing grade of 70% or higher on the posttest.
Articles in this issue
about 13 years ago
Optimizing Therapy and Management of Neurogenic Bladderabout 13 years ago
The Epidemiology and Pathophysiology of Neurogenic BladderAdvertisement
Related to this article
Employer-mandated enrollment in a high-deductible health plan did not reduce use of oral targeted anticancer medications among patients commercially insured between 2007 and 2021.
We identify the health system characteristics associated with greater or lesser documentation of patients’ social determinants of health.
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
3
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
4
Preparing Practices for the Next Era of Hepatitis B Care
5